Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

1.810 +0.490 (+37.12%)
Official Closing Price Updated: 7:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Via Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via GlobeNewswire
A Preview Of ADC Therapeutics's Earnings
Via Benzinga
4 Analysts Have This to Say About ADC Therapeutics
Via Benzinga
Earnings Preview: ADC Therapeutics
Via Benzinga
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
From ADC Therapeutics SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
From ADC Therapeutics SA
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with... 
Via Benzinga
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P... 
Via Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday. 
Via Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also... 
Via Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to... 
Via Benzinga
ADC Therapeutics Stock Is Plunging Today - What's Going On?
ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or... 
Via Benzinga
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML 
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics to Participate in the Jefferies Healthcare Conference
From ADC Therapeutics SA
Via GlobeNewswire
ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports First Quarter 2023 Financial Results and Provides Business and Strategy Update
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics to Host First Quarter 2023 Financial Results Conference Call on May 9, 2023
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022
From ADC Therapeutics SA
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023
Via Benzinga
ADC Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
From ADC Therapeutics SA
Via Business Wire
ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
From ADC Therapeutics SA
Via Business Wire
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday's morning session saw 84 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.